[Immunoscintigraphy with radionuclide-labeled monoclonal antibodies for tumor diagnosis and in benign diseases].
Immunoscintigraphy using radiolabeled (technetium-99m, indium-111, iodine-131) monoclonal antibodies is successfully (sensitivity over 80%, specificity over 90%) applied since some years in the clinic for the detection of CEA- and or CA 19-9-producing colorectal and CA 125-positive ovarian carcinoma recurrences and just recently for the diagnosis of benign diseases (myocardial infarction/transplant rejection/thrombosis/abscess localization.